The U.S. Food and Drug Administration said Tuesday it has identified about 20 drug products that either solely source their active ingredients or produce finished drug products in China and has contacted their manufacturers to see if they have experienced any supply issues, FDA spokesperson Stephanie Caccomo said in a statement.